09:18 AM EST, 01/30/2025 (MT Newswires) -- Tectonic Therapeutic ( TECX ) shares climbed 90% in Thursday's premarket session after the company said a phase 1b trial showed that TX45 improved left ventricular function and pulmonary hemodynamics.

The biotech firm said TX45 was well tolerated with no serious or severe adverse events, discontinuations, infusion reactions, or drug-related adverse events.

"These interim results show that TX45 achieved improvements in hemodynamics which met and exceeded our prespecified objectives," Chief Executive Alise Reicin said in a release.